Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications linking product attributes threshold pricing model how commercial thresholds can inform
2023 Italian Society of Hygiene, Preventive Medicine, and Public Health (SITI) Conference Share on: Thursday, October 12 - Saturday, October 14, 2023 Conference website Research coauthored by RTI Health Solutions experts will be presented at the 2023 …
… How Are Companies Responding to Expected Challenges with …
… requirements and procedures for HTAs, market access, and pricing across Europe. In addition, the European Union (EU) … use of comparative clinical trials, among other factors. How is the Pharmaceutical Industry Responding to These New … Supporting clients through the entire life cycle of a new product is a particular strength of RTI Health Solutions. …
… for a successful launch, a Market Access Evidence Roadmap can help you identify areas of evidence generation required … to support reimbursement and increase access to your product. What you will learn during this 1-hour session: What … in key markets What Market Access Evidence Roadmaps are How they are developed and applied Their overall role in …
… it is particularly challenging to demonstrate sufficient product value to support successful reimbursement and patient … a strategic plan with a Market Access Evidence Roadmap can help you identify areas of evidence generation you will … in developing a reimbursement strategy for orphan drugs - How they are developed and applied HTA requirements in key …
… to patients and providers, navigating the HTA process can be a significant hurdle. They often find themselves … digital therapeutics, and devices all treated the same? How different are the requirements from country to country? … on how to be prepared for HTA success for your medtech product. Join us for this webinar where you’ll learn: The …
… Using Real-World Data A Challenge of Real World Data: How to Assign Individuals to a Treatment Strategy When Their … because only people who live for a long time can receive treatment for a long time. A way to … cancer-specific mortality. We found that random assignment can be a valid alternative to cloning at baseline. The …
… Manage Your Established Product …
… a retrospective cohort study of CLL patients using a commercial claims database in the US. Our study includes … shifting as treatment guidelines change. Learn more about how RTI Health Solutions can help you with retrospective cohort studies or any …
2023 Respiratory Synctial Virus Foundation (RSVVW) Share on: Wednesday, February 22 - Friday, February 24, 2023 Conference Website Research coauthored by RTI Health Solutions researchers will be presented at the 2023 Respiratory Synctial Virus …